BMEA

Biomea Fusion Inc · NASDAQ

Performance

-0.75%

1W

-18.82%

1M

-18.26%

3M

+9.83%

6M

-13.84%

YTD

-50.0%

1Y

Profile

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Investment Analysis Report: BMEA

Overview

BMEA is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has shown significant growth in its financial metrics over the past three years, with a notable increase in total assets, revenue, and cash flow. In this report, we will conduct a...

See more ...

Technical Analysis of BMEA 2024-04-12

Overview:

In analyzing the technical indicators for BMEA stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potenti...

See more ...

Recent News & Updates